The ANDROMEDA trial, sponsored by AstraZeneca, is a pivotal Phase I/II study evaluating AZD9750, an innovative AR-PROTAC, for the treatment of metastatic prostate cancer. Given the increasing prevalence of prostate cancer and the limitations of current therapies, AZD9750 represents a potentially significant advancement in the therapeutic landscape. The modular design allows for flexible exploration of monotherapy and combination strategies, particularly with saruparib, a PARP inhibitor. The trial's success could position AstraZeneca favorably against competitors in the prostate cancer space, particularly those focusing on AR-targeted therapies. The estimated enrollment of 300 participants and the ongoing recruitment across multiple global sites underscore the strategic importance of this asset in AstraZeneca's oncology portfolio.